Literature DB >> 9652992

Report of the NIH Panel To Define Principles of Therapy of HIV Infection.

.   

Abstract

Recent research advances have afforded substantially improved understanding of the biology of HIV infection and the pathogenesis of AIDS. With the advent of sensitive tools for monitoring HIV replication in infected persons, the risk for disease progression and death can be assessed accurately and the efficacy of anti-HIV therapies can be determined directly. Furthermore, when used appropriately, combinations of newly available, potent antiviral therapies can effect prolonged suppression of detectable levels of HIV replication and circumvent the inherent tendency of HIV to generate drug-resistant viral variants. However, as antiretroviral therapy for HIV infection has become increasingly effective, it has also become increasingly complex. Familiarity with recent research advances is needed to ensure that newly available therapies are used in ways that most effectively improve the health and prolong the lives of HIV-infected persons. To enable practitioners and HIV-infected persons to best use rapidly accumulating new information about HIV disease pathogenesis and treatment, the Office of AIDS Research of the National Institutes of Health (NIH) sponsored the NIH Panel To Define Principles of Therapy of HIV Infection. This Panel was asked to define essential scientific principles that should be used to guide the most effective use of antiretroviral therapies and viral load testing in clinical practice. On the basis of detailed consideration of the most current data, the Panel delineated 11 principles that address issues of fundamental importance for the treatment of HIV infection. These principles provide the scientific basis for the specific treatment recommendations made by the Panel on Clinical Practices for the Treatment of HIV Infection sponsored by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation. The reports of both of these panels are provided in this supplement. Together, they summarize new data and provide both the scientific basis and specific guidelines for the treatment of HIV-infected persons. This information will be of interest to health care providers, HIV-infected persons, HIV and AIDS educators, public health educators, public health authorities, and all organizations that fund medical care of HIV-infected persons.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652992     DOI: 10.7326/0003-4819-128-12_part_2-199806151-00002

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  Immune Reconstitution and the Consequences for Opportunistic Infection Treatment and Prevention.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

2.  Production of resistant HIV mutants during antiretroviral therapy.

Authors:  R M Ribeiro; S Bonhoeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Problem drinking and medication adherence among persons with HIV infection.

Authors:  R L Cook; S M Sereika; S C Hunt; W C Woodward; J A Erlen; J Conigliaro
Journal:  J Gen Intern Med       Date:  2001-02       Impact factor: 5.128

4.  Physician specialization and antiretroviral therapy for HIV.

Authors:  Bruce E Landon; Ira B Wilson; Susan E Cohn; Carl J Fichtenbaum; Mitchell D Wong; Neil S Wenger; Samuel A Bozzette; Martin F Shapiro; Paul D Cleary
Journal:  J Gen Intern Med       Date:  2003-04       Impact factor: 5.128

5.  Does racial concordance between HIV-positive patients and their physicians affect the time to receipt of protease inhibitors?

Authors:  William D King; Mitchell D Wong; Martin F Shapiro; Bruce E Landon; William E Cunningham
Journal:  J Gen Intern Med       Date:  2004-11       Impact factor: 5.128

Review 6.  Youths and HIV/AIDS: psychiatry's role in a changing epidemic.

Authors:  Geri R Donenberg; Maryland Pao
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-08       Impact factor: 8.829

7.  Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients.

Authors:  Mitchell D Wong; William E Cunningham; Martin F Shapiro; Ronald M Andersen; Paul D Cleary; Naihua Duan; Hong Hu Liu; Ira B Wilson; Bruce E Landon; Neil S Wenger
Journal:  J Gen Intern Med       Date:  2004-04       Impact factor: 5.128

8.  Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy.

Authors:  Marek Fischer; Beda Joos; Barbara Niederöst; Philipp Kaiser; Roland Hafner; Viktor von Wyl; Martina Ackermann; Rainer Weber; Huldrych F Günthard
Journal:  Retrovirology       Date:  2008-11-26       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.